| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
261.92(M) |
| Last
Volume: |
1,607,087 |
Avg
Vol: |
2,316,426 |
| 52
Week Range: |
$0.449 - $1.67 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
36,653 |
73,355 |
186,690 |
544,022 |
| Total Sell Value |
$24,924 |
$42,909 |
$121,964 |
$1,484,432 |
| Total People Sold |
3 |
3 |
6 |
11 |
| Total Sell Transactions |
3 |
6 |
15 |
39 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2020-08-17 |
4 |
S |
$19.67 |
$30,075 |
D/D |
(1,529) |
51,389 |
|
7% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2020-08-17 |
4 |
S |
$19.67 |
$26,889 |
D/D |
(1,367) |
171,733 |
|
7% |
|
| Greer R Scott |
Director |
– • – |
2020-07-09 |
4 |
AS |
$25.00 |
$375,225 |
D/D |
(15,009) |
176,574 |
|
-30% |
|
| Greer R Scott |
Director |
– • – |
2020-07-09 |
4 |
OE |
$9.24 |
$369,600 |
D/D |
40,000 |
191,583 |
|
- |
|
| Chess Robert |
Director |
– • – |
2020-07-08 |
4 |
AS |
$24.58 |
$196,640 |
D/D |
(8,000) |
276,973 |
|
-29% |
|
| Chess Robert |
Director |
– • – |
2020-07-08 |
4 |
OE |
$9.24 |
$73,920 |
D/D |
8,000 |
284,973 |
|
- |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2020-05-19 |
4 |
AS |
$22.62 |
$45,240 |
D/D |
(2,000) |
245,494 |
|
-24% |
|
| Wilson Mark Andrew |
SVP & General Counsel |
• – – |
2020-05-18 |
4 |
S |
$22.51 |
$34,418 |
D/D |
(1,529) |
52,418 |
|
23% |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2020-05-18 |
4 |
S |
$22.51 |
$102,601 |
D/D |
(4,558) |
322,515 |
|
23% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2020-05-18 |
4 |
S |
$22.51 |
$30,771 |
D/D |
(1,367) |
172,719 |
|
23% |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2020-05-18 |
4 |
AS |
$22.51 |
$128,915 |
D/D |
(5,727) |
247,494 |
|
-23% |
|
| Robin Howard W |
President & CEO |
• • – |
2020-05-18 |
4 |
S |
$22.51 |
$201,870 |
D/D |
(8,968) |
375,903 |
|
23% |
|
| Chess Robert |
Director |
– • – |
2020-04-15 |
4 |
AS |
$18.36 |
$147,010 |
D/D |
(8,000) |
276,973 |
|
4% |
|
| Chess Robert |
Director |
– • – |
2020-04-15 |
4 |
OE |
$9.24 |
$73,920 |
D/D |
8,000 |
284,973 |
|
- |
|
| Wilson Mark Andrew |
SVP & General CounselOfficer |
• – – |
2020-03-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
53,947 |
|
22% |
|
| Chess Robert |
Director |
– • – |
2020-03-11 |
4 |
AS |
$16.68 |
$134,316 |
D/D |
(8,000) |
276,973 |
|
48% |
|
| Chess Robert |
Director |
– • – |
2020-03-11 |
4 |
OE |
$9.24 |
$73,920 |
D/D |
8,000 |
284,973 |
|
- |
|
| Zalevsky Jonathan |
Chief R&D Officer |
• – – |
2020-02-18 |
4 |
S |
$22.35 |
$106,699 |
D/D |
(4,774) |
327,073 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2020-02-18 |
4 |
S |
$22.35 |
$188,813 |
D/D |
(8,448) |
384,871 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2020-02-18 |
4 |
S |
$22.35 |
$31,156 |
D/D |
(1,394) |
174,086 |
|
- |
|
| Labrucherie Gil M |
SVP, COO & CFO |
• – – |
2020-02-18 |
4 |
S |
$22.35 |
$132,714 |
D/D |
(5,938) |
253,221 |
|
- |
|
| Chess Robert |
Director |
– • – |
2020-02-12 |
4 |
AS |
$23.32 |
$188,000 |
D/D |
(8,000) |
276,973 |
|
-2% |
|
| Chess Robert |
Director |
– • – |
2020-02-12 |
4 |
OE |
$9.24 |
$73,920 |
D/D |
8,000 |
284,973 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2020-02-06 |
4 |
AS |
$22.78 |
$854,250 |
D/D |
(37,500) |
175,480 |
|
-2% |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2020-02-06 |
4 |
OE |
$7.21 |
$270,375 |
D/D |
37,500 |
212,980 |
|
- |
|
909 Records found
|
|
Page 8 of 37 |
|
|
0.14 (10.61%) 
